VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Dec. 6, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced IRB (Institutional Review Board) approval to begin enrolling patients for a Phase II human clinical trial evaluating the Company's lead product AL-108. The trial will evaluate the efficacy of AL-108 in improving cognitive function in patients who suffer from Mild Cognitive Impairment (MCI), often a pre-cursor to Alzheimer's disease.
